Abstract
Atopic dermatitis (AD) is a chronic inflammatory skin disease with specific immune and inflammatory mechanisms. Atopy is among the major features of the diagnosis criteria for AD but is not an essential feature. Thus, patients diagnosed with AD can be atopic or non-atopic. This review focuses on the role of IgE, mast cells, and eosinophils in the pathogenesis of AD. The known functions of IgE in allergic inflammation suggest that IgE and IgE-mediated mast cell and eosinophil activation contribute to AD, but direct evidence supporting this is scarce. The level of IgE (thus the degree of allergic sensitization) is associated with severity of AD and contributed by abnormality of skin barrier, a key feature of AD. The function of IgE in development of AD is supported by the beneficial effect of anti-IgE therapy in a number of clinical studies. The role of mast cells in AD is suggested by the increase in the mast cell number and mast cell activation in AD lesions and the association between mast cell activation and AD. It is further suggested by their role in mouse models of AD as well as by the effect of therapeutic agents for AD that can affect mast cells. The role of eosinophils in AD is suggested by the presence of eosinophilia in AD patients and eosinophil infiltrates in AD lesions. It is further supported by information that links AD to cytokines and chemokines associated with production, recruitment, and activation of eosinophils.
Similar content being viewed by others
References
Hanifin JM, Rajka G (1980) Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 92:44–47
Williams HC (2005) Clinical practice. Atopic dermatitis. N Engl J Med 352(22):2314–2324
Eichenfield LF et al (2003) Consensus conference on pediatric atopic dermatitis. J Am Acad Dermatol 49(6):1088–1095
Schafer T et al (1999) Association between severity of atopic eczema and degree of sensitization to aeroallergens in schoolchildren. J Allergy Clin Immunol 104(6):1280–1284
Laske N, Niggemann B (2004) Does the severity of atopic dermatitis correlate with serum IgE levels? Pediatr Allergy Immunol 15(1):86–88
Hill DJ, Hosking CS (2004) Food allergy and atopic dermatitis in infancy: an epidemiologic study. Pediatr Allergy Immunol 15(5):421–427
Illi S et al (2004) The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. J Allergy Clin Immunol 113(5):925–931
Wang IJ et al (2004) Correlation between age and allergens in pediatric atopic dermatitis. Ann Allergy Asthma Immunol 93(4):334–338
Johnke H et al (2006) Patterns of sensitization in infants and its relation to atopic dermatitis. Pediatr Allergy Immunol 17(8):591–600
Eller E et al (2009) Development of atopic dermatitis in the DARC birth cohort. Pediatr Allergy Immunol 21:307–314
Kjaer HF et al (2009) The association between early sensitization patterns and subsequent allergic disease. The DARC birth cohort study. Pediatr Allergy Immunol 20(8):726–734
Somani VK (2008) A study of allergen-specific IgE antibodies in Indian patients of atopic dermatitis. Indian J Dermatol Venereol Leprol 74(2):100–104
Hill DJ et al (2008) Confirmation of the association between high levels of immunoglobulin E food sensitization and eczema in infancy: an international study. Clin Exp Allergy 38(1):161–168
Osterballe M et al (2009) The prevalence of food hypersensitivity in young adults. Pediatr Allergy Immunol 20(7):686–692
Flohr C et al (2004) How atopic is atopic dermatitis? J Allergy Clin Immunol 114(1):150–158
Johansson SG et al (2004) Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 113(5):832–836
Laske N, Bunikowski R, Niggemann B (2003) Extraordinarily high serum IgE levels and consequences for atopic phenotypes. Ann Allergy Asthma Immunol 91(2):202–204
Wahn U et al (2008) IgE antibody responses in young children with atopic dermatitis. Pediatr Allergy Immunol 19(4):332–336
Elias PM, Feingold KR (2001) Does the tail wag the dog? Role of the barrier in the pathogenesis of inflammatory dermatoses and therapeutic implications. Arch Dermatol 137(8):1079–1081
O'Regan GM et al (2008) Filaggrin in atopic dermatitis. J Allergy Clin Immunol 122(4):689–693
van den Oord RA, Sheikh A (2009) Filaggrin gene defects and risk of developing allergic sensitisation and allergic disorders: systematic review and meta-analysis. BMJ 339:b2433
Leung DY et al (1993) Presence of IgE antibodies to staphylococcal exotoxins on the skin of patients with atopic dermatitis. Evidence for a new group of allergens. J Clin Invest 92(3):1374–1380
TADA J et al (1996) Presence of specific IgE antibodies to staphylococcal enterotoxins in patients with atopic dermatitis. Eur J Dermatol 6:552–554
Bunikowski R et al (1999) Prevalence and role of serum IgE antibodies to the Staphylococcus aureus-derived superantigens SEA and SEB in children with atopic dermatitis. J Allergy Clin Immunol 103(1 Pt 1):119–124
Ide F et al (2004) Staphylococcal enterotoxin-specific IgE antibodies in atopic dermatitis. Pediatr Int 46(3):337–341
Clark RA, Adinoff AD (1989) Aeroallergen contact can exacerbate atopic dermatitis: patch tests as a diagnostic tool. J Am Acad Dermatol 21(4 Pt 2):863–869
Sanda T et al (1992) Effectiveness of house dust-mite allergen avoidance through clean room therapy in patients with atopic dermatitis. J Allergy Clin Immunol 89(3):653–657
Tan BB et al (1996) Double-blind controlled trial of effect of housedust-mite allergen avoidance on atopic dermatitis. Lancet 347(8993):15–18
Nolles G et al (2001) Prevalence of immunoglobulin E for fungi in atopic children. Clin Exp Allergy 31(10):1564–1570
Wessels MW et al (1991) IgE antibodies to Pityrosporum ovale in atopic dermatitis. Br J Dermatol 125(3):227–232
Jensen-Jarolim E et al (1992) Atopic dermatitis of the face, scalp, and neck: type I reaction to the yeast Pityrosporum ovale? J Allergy Clin Immunol 89(1 Pt 1):44–51
Scalabrin DM et al (1999) Use of specific IgE in assessing the relevance of fungal and dust mite allergens to atopic dermatitis: a comparison with asthmatic and nonasthmatic control subjects. J Allergy Clin Immunol 104(6):1273–1279
Arzumanyan VG et al (2003) IgE and IgG antibodies to Malassezia spp. yeast extract in patients with atopic dermatitis. Bull Exp Biol Med 135(5):460–463
Savolainen J et al (1993) Candida albicans and atopic dermatitis. Clin Exp Allergy 23(4):332–339
Reefer AJ et al (2007) The relevance of microbial allergens to the IgE antibody repertoire in atopic and nonatopic eczema. J Allergy Clin Immunol 120(1):156–163
Valenta R et al (1996) Immunoglobulin E response to human proteins in atopic patients. J Invest Dermatol 107(2):203–208
Valenta R et al (1997) Isolation of cDNAs coding for IgE autoantigens: a link between atopy and autoimmunity. Int Arch Allergy Immunol 113(1–3):209–212
Altrichter S et al (2008) Serum IgE autoantibodies target keratinocytes in patients with atopic dermatitis. J Invest Dermatol 128(9):2232–2239
Valenta R et al (1998) Molecular characterization of an autoallergen, Hom s 1, identified by serum IgE from atopic dermatitis patients. J Invest Dermatol 111(6):1178–1183
Natter S et al (1998) Isolation of cDNA clones coding for IgE autoantigens with serum IgE from atopic dermatitis patients. FASEB J 12(14):1559–1569
Valenta R et al (1991) Identification of profilin as a novel pollen allergen; IgE autoreactivity in sensitized individuals. Science 253(5019):557–560
Crameri R et al (1996) Humoral and cell-mediated autoimmunity in allergy to Aspergillus fumigatus. J Exp Med 184(1):265–270
Seiberler S et al (1999) Characterization of IgE-reactive autoantigens in atopic dermatitis. 1. Subcellular distribution and tissue-specific expression. Int Arch Allergy Immunol 120(2):108–116
Novak N, Bieber T, Kraft S (2004) Immunoglobulin E-bearing antigen-presenting cells in atopic dermatitis. Curr Allergy Asthma Rep 4(4):263–269
Kolmer HL et al (1996) Effect of combined antibacterial and antifungal treatment in severe atopic dermatitis. J Allergy Clin Immunol 98(3):702–707
Spergel JM et al (1999) Roles of TH1 and TH2 cytokines in a murine model of allergic dermatitis. J Clin Invest 103(8):1103–1111
MacGlashan DW Jr et al (1997) Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 158(3):1438–1445
Beck LA et al (2004) Omalizumab-induced reductions in mast cell Fce psilon RI expression and function. J Allergy Clin Immunol 114(3):527–530
Krathen RA, Hsu S (2005) Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol 53(2):338–340
Beck LA, Saini S (2006) Wanted: a study with omalizumab to determine the role of IgE-mediated pathways in atopic dermatitis. J Am Acad Dermatol 55(3):540–541, author reply 541–2
Lane JE et al (2006) Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 54(1):68–72
Vigo PG et al (2006) Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol 55(1):168–170
Belloni B et al (2007) Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 120(5):1223–1225
Forman SB, Garrett AB (2007) Success of omalizumab as monotherapy in adult atopic dermatitis: case report and discussion of the high-affinity immunoglobulin E receptor, FcepsilonRI. Cutis 80(1):38–40
Incorvaia C et al (2008) Effectiveness of omalizumab in a patient with severe asthma and atopic dermatitis. Monaldi Arch Chest Dis 69(2):78–80
Sheinkopf LE et al (2008) Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. Allergy Asthma Proc 29(5):530–537
Walsh LJ et al (1991) Human dermal mast cells contain and release tumor necrosis factor alpha, which induces endothelial leukocyte adhesion molecule 1. Proc Natl Acad Sci USA 88(10):4220–4224
Schleimer RP et al (1992) IL-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium. Association with expression of VCAM-1. J Immunol 148(4):1086–1092
Sironi M et al (1994) Regulation of endothelial and mesothelial cell function by interleukin-13: selective induction of vascular cell adhesion molecule-1 and amplification of interleukin-6 production. Blood 84(6):1913–1921
Nakae S et al (2006) Mast cells enhance T cell activation: importance of mast cell costimulatory molecules and secreted TNF. J Immunol 176(4):2238–2248
Nakae S et al (2005) Mast cells enhance T cell activation: importance of mast cell-derived TNF. Proc Natl Acad Sci USA 102(18):6467–6472
Mekori YA, Metcalfe DD (1999) Mast cell–T cell interactions. J Allergy Clin Immunol 104(3 Pt 1):517–523
Tkaczyk C et al (1996) Mouse bone marrow-derived mast cells and mast cell lines constitutively produce B cell growth and differentiation activities. J Immunol 157(4):1720–1728
Pawankar R et al (1997) Nasal mast cells in perennial allergic rhinitics exhibit increased expression of the Fc epsilonRI, CD40L, IL-4, and IL-13, and can induce IgE synthesis in B cells. J Clin Invest 99(7):1492–1499
Gauchat JF et al (1993) Induction of human IgE synthesis in B cells by mast cells and basophils. Nature 365(6444):340–343
Kohda F et al (2002) Histamine-induced IL-6 and IL-8 production are differentially modulated by IFN-gamma and IL-4 in human keratinocytes. J Dermatol Sci 28(1):34–41
Kanda N, Watanabe S (2004) Histamine enhances the production of granulocyte-macrophage colony-stimulating factor via protein kinase C alpha and extracellular signal-regulated kinase in human keratinocytes. J Invest Dermatol 122(4):863–872
Ioffreda MD, Whitaker D, Murphy GF (1993) Mast cell degranulation upregulates alpha 6 integrins on epidermal Langerhans cells. J Invest Dermatol 101(2):150–154
Jawdat DM et al (2004) IgE-mediated mast cell activation induces Langerhans cell migration in vivo. J Immunol 173(8):5275–5282
Suto H et al (2006) Mast cell-associated TNF promotes dendritic cell migration. J Immunol 176(7):4102–4112
Mazzoni A et al (2006) Dendritic cell modulation by mast cells controls the Th1/Th2 balance in responding T cells. J Immunol 177(6):3577–3581
Theiner G, Gessner A, Lutz MB (2006) The mast cell mediator PGD2 suppresses IL-12 release by dendritic cells leading to Th2 polarized immune responses in vivo. Immunobiology 211(6–8):463–472
Frandji P et al (1993) Antigen-dependent stimulation by bone marrow-derived mast cells of MHC class II-restricted T cell hybridoma. J Immunol 151(11):6318–6328
Fox CC, Jewell SD, Whitacre CC (1994) Rat peritoneal mast cells present antigen to a PPD-specific T cell line. Cell Immunol 158(1):253–264
Frandji P et al (1995) Presentation of soluble antigens by mast cells: upregulation by interleukin-4 and granulocyte/macrophage colony-stimulating factor and downregulation by interferon-gamma. Cell Immunol 163(1):37–46
Frandji P et al (1996) Exogenous and endogenous antigens are differentially presented by mast cells to CD4+ T lymphocytes. Eur J Immunol 26(10):2517–2528
Malaviya R et al (1996) Mast cells process bacterial Ags through a phagocytic route for class I MHC presentation to T cells. J Immunol 156(4):1490–1496
Soter NA (1989) Morphology of atopic eczema. Allergy 44(Suppl 9):16–19
Irani AM, Sampson HA, Schwartz LB (1989) Mast cells in atopic dermatitis. Allergy 44(Suppl 9):31–34
Groneberg DA et al (2005) Mast cells and vasculature in atopic dermatitis—potential stimulus of neoangiogenesis. Allergy 60(1):90–97
Cox HE et al (1998) Association of atopic dermatitis to the beta subunit of the high affinity immunoglobulin E receptor. Br J Dermatol 138(1):182–187
Mao XQ et al (1996) Association between genetic variants of mast-cell chymase and eczema. Lancet 348(9027):581–583
Badertscher K et al (2005) Mast cell chymase is increased in chronic atopic dermatitis but not in psoriasis. Arch Dermatol Res 296(10):503–506
Zhao L et al (2006) A rodent model for allergic dermatitis induced by flea antigens. Vet Immunol Immunopathol 114(3–4):285–296
Kanbe T et al (2001) Serum levels of soluble stem cell factor and soluble KIT are elevated in patients with atopic dermatitis and correlate with the disease severity. Br J Dermatol 144(6):1148–1153
Ring J, Thomas P (1989) Histamine and atopic eczema. Acta Derm Venereol Suppl Stockh 144:70–77
Hamid Q et al (1996) In vivo expression of IL-12 and IL-13 in atopic dermatitis. J Allergy Clin Immunol 98(1):225–231
Hamid Q, Boguniewicz M, Leung DY (1994) Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J Clin Invest 94(2):870–876
Horsmanheimo L et al (1994) Mast cells are one major source of interleukin-4 in atopic dermatitis. Br J Dermatol 131(3):348–353
Steinhoff M et al (2003) Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. J Neurosci 23(15):6176–6180
Gombert M et al (2005) CCL1-CCR8 interactions: an axis mediating the recruitment of T cells and Langerhans-type dendritic cells to sites of atopic skin inflammation. J Immunol 174(8):5082–5091
Groneberg DA et al (2003) Down-regulation of vasoactive intestinal polypeptide receptor expression in atopic dermatitis. J Allergy Clin Immunol 111(5):1099–1105
Lewis RA, Austen KF (1981) Mediation of local homeostasis and inflammation by leukotrienes and other mast cell-dependent compounds. Nature 293(5828):103–108
Fischer M et al (2006) Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion. J Clin Investig 116(10):2748–2756
Kawakami T et al (2009) Mast cells in atopic dermatitis. Curr Opin Immunol 21:666–678
Chan LS, Robinson N, Xu LT (2001) Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis. J Investig Dermatol 117(4):977–983
Zheng T et al (2009) Transgenic expression of interleukin-13 in the skin induces a pruritic dermatitis and skin remodeling. J Invest Dermatol 129(3):742–751
Morioka T et al (2009) IL-4/IL-13 antagonist DNA vaccination successfully suppresses Th2 type chronic dermatitis. Br J Dermatol 160(6):1172–1179
Tam SY et al (2004) RabGEF1 is a negative regulator of mast cell activation and skin inflammation. Nat Immunol 5(8):844–852
Alenius H et al (2002) Mast cells regulate IFN-gamma expression in the skin and circulating IgE levels in allergen-induced skin inflammation. J Allergy Clin Immunol 109(1):106–113
Matsuda H et al (1997) Development of atopic dermatitis-like skin lesion with IgE hyperproduction in NC/Nga mice. Int Immunol 9(3):461–466
Matsuoka H et al (2003) A mouse model of the atopic eczema/dermatitis syndrome by repeated application of a crude extract of house-dust mite Dermatophagoides farinae. Allergy 58(2):139–145
Terada M et al (2006) Contribution of IL-18 to atopic-dermatitis-like skin inflammation induced by Staphylococcus aureus product in mice. Proc Natl Acad Sci USA 103(23):8816–8821
Terakawa M et al (2008) Oral chymase inhibitor SUN13834 ameliorates skin inflammation as well as pruritus in mouse model for atopic dermatitis. Eur J Pharmacol 601(1–3):186–191
Watanabe N et al (2002) Chymase inhibitor improves dermatitis in NC/Nga mice. Int Arch Allergy Immunol 128(3):229–234
Kim Y et al (2008) Hyaluronic acid targets CD44 and inhibits FcepsilonRI signaling involving PKCdelta, Rac1, ROS, and MAPK to exert anti-allergic effect. Mol Immunol 45(9):2537–2547
Schleimer RP et al (1983) Effects of dexamethasone on mediator release from human lung fragments and purified human lung mast cells. J Clin Invest 71(6):1830–1835
Smith SJ et al (2002) Dexamethasone inhibits maturation, cytokine production and Fc epsilon RI expression of human cord blood-derived mast cells. Clin Exp Allergy 32(6):906–913
Kato A et al (2009) Dexamethasone and FK506 inhibit expression of distinct subsets of chemokines in human mast cells. J Immunol 182(11):7233–7243
Gisondi P, Ellis CN, Girolomoni G (2005) Pimecrolimus in dermatology: atopic dermatitis and beyond. Int J Clin Pract 59(8):969–974
Sardy M, Ruzicka T, Kuhn A (2009) Topical calcineurin inhibitors in cutaneous lupus erythematosus. Arch Dermatol Res 301(1):93–98
Simon D et al (2004) Reduced dermal infiltration of cytokineexpressing inflammatory cells in atopic dermatitis after short-term topical tacrolimus treatment. J Allergy Clin Immunol 114(4):887–895
Denburg JA et al (1985) Heterogeneity of human peripheral blood eosinophil-type colonies: evidence for a common basophil-eosinophil progenitor. Blood 66(2):312–318
Young B (2006) Wheater’s functional histology: a text and colour atlas, 5th edn. Churchill Livingstone/Elsevier, Edinburgh, p 437
Leiferman KM (1991) A current perspective on the role of eosinophils in dermatologic diseases. J Am Acad Dermatol 24(6 Pt 2):1101–1112
Zheutlin LM et al (1984) Stimulation of basophil and rat mast cell histamine release by eosinophil granule-derived cationic proteins. J Immunol 133(4):2180–2185
Moy JN, Gleich GJ, Thomas LL (1990) Noncytotoxic activation of neutrophils by eosinophil granule major basic protein. Effect on superoxide anion generation and lysosomal enzyme release. J Immunol 145(8):2626–2632
Rohrbach MS et al (1990) Activation of platelets by eosinophil granule proteins. J Exp Med 172(4):1271–1274
Kita H et al (1995) Eosinophil major basic protein induces degranulation and IL-8 production by human eosinophils. J Immunol 154(9):4749–4758
Kato M et al (1998) Eosinophil infiltration and degranulation in normal human tissue. Anat Rec 252(3):418–425
Kagi MK, Joller-Jemelka H, Wuthrich B (1992) Correlation of eosinophils, eosinophil cationic protein and soluble interleukin-2 receptor with the clinical activity of atopic dermatitis. Dermatology 185(2):88–92
Uehara M, Izukura R, Sawai T (1990) Blood eosinophilia in atopic dermatitis. Clin Exp Dermatol 15(4):264–266
Nishimoto M et al (1998) Peripheral eosinophil counts relates the improvement of the skin lesions of atopic dermatitis patients more sensitive than serum eosinophil cationic protein levels. Arerugi 47(6):591–596
Borres MP, Bjorksten B (2004) Peripheral blood eosinophils and IL-4 in infancy in relation to the appearance of allergic disease during the first 6 years of life. Pediatr Allergy Immunol 15(3):216–220
Leiferman KM et al (1985) Dermal deposition of eosinophil-granule major basic protein in atopic dermatitis. Comparison with onchocerciasis. N Engl J Med 313(5):282–285
Leiferman KM (2001) A role for eosinophils in atopic dermatitis. J Am Acad Dermatol 45(1 Suppl):S21–S24
Pucci N et al (2000) Urinary eosinophil protein X and serum eosinophil cationic protein in infants and young children with atopic dermatitis: correlation with disease activity. J Allergy Clin Immunol 105(2 Pt 1):353–357
Breuer K, Kapp A, Werfel T (2001) Urine eosinophil protein X (EPX) is an in vitro parameter of inflammation in atopic dermatitis of the adult age. Allergy 56(8):780–784
Goto T et al (2007) Urinary eosinophil-derived neurotoxin concentrations in patients with atopic dermatitis: a useful clinical marker for disease activity. Allergol Int 56(4):433–438
Czech W et al (1992) Serum eosinophil cationic protein (ECP) is a sensitive measure for disease activity in atopic dermatitis. Br J Dermatol 126(4):351–355
Wassom DL et al (1981) Elevated serum levels of the eosinophil granule major basic protein in patients with eosinophilia. J Clin Invest 67(3):651–661
Taniuchi S et al (2001) Serum eosinophil derived neurotoxin may reflect more strongly disease severity in childhood atopic dermatitis than eosinophil cationic protein. J Dermatol Sci 26(1):79–82
Oymar K, Bjerknes R (2000) Urinary eosinophil protein X in children with atopic dermatitis: relation to atopy and disease activity. Allergy 55(10):964–968
Halmerbauer G, Frischer T, Koller DY (1997) Monitoring of disease activity by measurement of inflammatory markers in atopic dermatitis in childhood. Allergy 52(7):765–769
Caproni M et al (1996) Modulation of serum eosinophil cationic protein levels by cyclosporin in severe atopic dermatitis. Br J Dermatol 135(2):336–337
Bradding P et al (1994) Interleukin-4, −5, and −6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol 10(5):471–480
Nishinakamura R et al (1996) Hematopoiesis in mice lacking the entire granulocyte-macrophage colony-stimulating factor/interleukin-3/interleukin-5 functions. Blood 88(7):2458–2464
Simon D, Braathen LR, Simon HU (2004) Eosinophils and atopic dermatitis. Allergy 59(6):561–570
Yamaguchi Y et al (1988) Highly purified murine interleukin 5 (IL-5) stimulates eosinophil function and prolongs in vitro survival. IL-5 as an eosinophil chemotactic factor. J Exp Med 167(5):1737–1742
Rothenberg ME, Hogan SP (2006) The eosinophil. Annu Rev Immunol 24:147–174
Yamamoto N et al (2003) Heterogeneity of interleukin 5 genetic background in atopic dermatitis patients: significant difference between those with blood eosinophilia and normal eosinophil levels. J Dermatol Sci 33(2):121–126
Amerio P et al (2003) Eotaxins and CCR3 receptor in inflammatory and allergic skin diseases: therapeutical implications. Curr Drug Targets Inflamm Allergy 2(1):81–94
Nonaka M et al (2004) Induction of eotaxin production by interleukin-4, interleukin-13 and lipopolysaccharide by nasal fibroblasts. Clin Exp Allergy 34(5):804–811
Teixeira MM et al (1997) Chemokine-induced eosinophil recruitment. Evidence of a role for endogenous eotaxin in an in vivo allergy model in mouse skin. J Clin Invest 100(7):1657–1666
Chihara J (1998) The role of chemokines such as RANTES in allergic disease. Rinsho Byori 46(8):816–820
Oyamada H et al (2006) RANTES production from mononuclear cells in response to the specific allergen in asthma patients. Allergol Int 55(3):253–259
Masuda K et al (2003) Increased levels of serum interleukin-16 in adult type atopic dermatitis. Acta Derm Venereol 83(4):249–253
Grewe M et al (1998) Human eosinophils produce biologically active IL-12: implications for control of T cell responses. J Immunol 161(1):415–420
Kang K, Stevens SR (2003) Pathophysiology of atopic dermatitis. Clin Dermatol 21(2):116–121
Elovic A et al (1994) Expression of transforming growth factors-alpha and beta 1 messenger RNA and product by eosinophils in nasal polyps. J Allergy Clin Immunol 93(5):864–869
Phipps S et al (2002) The relationship between allergen-induced tissue eosinophilia and markers of repair and remodeling in human atopic skin. J Immunol 169(8):4604–4612
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Liu, FT., Goodarzi, H. & Chen, HY. IgE, Mast Cells, and Eosinophils in Atopic Dermatitis. Clinic Rev Allerg Immunol 41, 298–310 (2011). https://doi.org/10.1007/s12016-011-8252-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12016-011-8252-4